# US 11,111,280 B2 · Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,280 B2
- Document ID: US11111280B2
- Status: Granted
- Kind: B2
- Application number: 16/851,976
- Filed: 2020-04-17
- Published: 2020-08-13
- Granted: 2021-09-07
- Earliest claimed: 2015-10-05
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Andrea Mahr; Toni Weinschenk; Valentina Goldfinger; Oliver Schoor; Jens Fritsche; Harpreet Singh
- Web page: https://patentgrep.com/patent/US11111280B2

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001152: {Transcription factors, e.g. SOX or c-MYC}
- A61K 39/001154: {Enzymes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules}
- C07K 16/30: from tumour cells
- C12N 5/0093: {Purging against cancer cells}
- C12N 5/0636: {T lymphocytes}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/62: DNA sequences coding for fusion proteins
- G01N 33/5752: of the lungs
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/86: {Lung}
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2310/16: Aptamers
- C12N 2510/00: Genetically modified cells
- G01N 2800/7028: Cancer
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that aberrantly present a peptide consisting of the amino acid sequence of SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20,
wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from the group consisting of lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells are autologous to the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the T cells are obtained from a healthy donor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the activated T cells are expanded in vitro.

### Claim 6 (depends on 1)

The method of claim 1, wherein the population of activated T cells are administered in the form of a composition.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition further comprises an adjuvant.

### Claim 8 (depends on 7)

The method of claim 7, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 9 (depends on 1)

The method of claim 1, wherein the contacting is in vitro.

### Claim 10

A method of eliciting an immune response in a patient who has lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, or prostate cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt and an adjuvant, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, thereby inducing a T-cell response to the lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, or prostate cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 11.

### Claim 12 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 12.

### Claim 13 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 13.

### Claim 14 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 14.

### Claim 15 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 15.

### Claim 16 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 16.

### Claim 17 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 17.

### Claim 18 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 18.

### Claim 19 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 19.

### Claim 20 (depends on 1)

The method of claim 1, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 20.

### Claim 21 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 22 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 23 (depends on 1)

The method of claim 1, wherein the cancer is liver cancer.

### Claim 24 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 25 (depends on 1)

The method of claim 1, wherein the cancer is uterine cancer.

### Claim 26 (depends on 1)

The method of claim 1, wherein the cancer is Merkel cell carcinoma.

### Claim 27 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic cancer.

### Claim 28 (depends on 1)

The method of claim 1, wherein the cancer is gallbladder cancer.

### Claim 29 (depends on 1)

The method of claim 1, wherein the cancer is bile duct cancer.

### Claim 30 (depends on 1)

The method of claim 1, wherein the cancer is colon or rectum cancer.

### Claim 31 (depends on 1)

The method of claim 1, wherein the cancer is urinary bladder cancer.

### Claim 32 (depends on 1)

The method of claim 1, wherein the cancer is kidney cancer.

### Claim 33 (depends on 1)

The method of claim 1, wherein the cancer is leukemia.

### Claim 34 (depends on 1)

The method of claim 1, wherein the cancer is ovarian cancer.

### Claim 35 (depends on 1)

The method of claim 1, wherein the cancer is esophageal cancer.

### Claim 36 (depends on 1)

The method of claim 1, wherein the cancer is brain cancer.

### Claim 37 (depends on 1)

The method of claim 1, wherein the cancer is gastric cancer.

### Claim 38 (depends on 1)

The method of claim 1, wherein the cancer is prostate cancer.